КОМОРБИДНЫЕ СОСТОЯНИЯ ПРИ ПСОРИАЗЕ

  • А. В. Брынина УО "Гродненский государственный медицинский университет" https://orcid.org/0000-0003-2394-404X
  • Д. Р. Гимхан Гродненский государственный медицинский университет, Гродно, Беларусь https://orcid.org/0000-0003-2027-8301
  • А. И. Викрамаге Гродненский государственный медицинский университет, Гродно, Беларусь https://orcid.org/0000-0001-8089-8575
Ключевые слова: псориаз, сопутствующие заболевания, комбинированная патология, сердечно-сосудистые заболевания, эндокринная патология, подагра, воспалительные заболевания кишечника

Аннотация

Псориаз – хронический дерматоз многофакторного характера с доминирующей ролью в развитии генетических факторов, характеризующийся гиперпролиферацией клеток эпидермиса, нарушением ороговения, воспалением в дерме. В настоящее время распространенность данного дерматоза среди населения составляет от 0,1 до 7%, а среди людей, госпитализированных в дерматологические стационары – от 25 до 40%. В научной литературе широко обсуждается вопрос рассмотрения псориаза как системного заболевания, которое включает повреждение не только кожи, но и других органов и систем. Таким образом, указанные проблемы сочетанной патологии актуальны, требуют дальнейшего углубленного изучения и поиска доказательных решений, которые позволят повысить качество медицинской помощи пациентам как только с псориазом, так и с его комбинированным течением.

Литература

Yiu ZZ, Warren RB. Ustekinumab for the treatment of psoriasis: an evidence update. Semin Cutan Med Surg. 2018;37(3):143-147. https://doi.org/10.12788/j.sder.2018.040.

Duodu P, Sosa G, Canar J, Chhugani O, Gamero AM. Exposing the Two Contrasting Faces of STAT2 in Inflammation. J Interferon Cytokine Res. 2022;42(9):467-481. https://doi.org/10.1089/jir.2022.0117.

Thye AY, Bah YR, Law JW, Tan LT, He YW, Wong SH, Thurairajasingam S, Chan KG, Lee LH, Letchumanan V. Gut Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis. Biomedicines. 2022;10(5):1037. https://doi.org/10.3390/biomedicines10051037.

Zhang LJ. Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. https://doi.org/10.3389/fimmu.2019.01440.

Nguyen CT, Bloch Y, Składanowska K, Savvides SN,Adamopoulos IE. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019;206:15-22. https://doi.org/10.1016/j.clim.2018.09.002.

Nussbaumerová B, Rosolová H. Diagnostika srdečního selhání: nová klasifikace srdečního selhání [Diagnosis of heart failure: the new classification of heart failure]. Vnitřní lékařství. 2018;64(9):847-851. (Czech).

Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021;8(2):e001735. https://doi.org/10.1136/openhrt-2021-001735.

Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314-319. doi:10.1111/bjd.12354.9. Talaee R, Hajheydari Z, Moghaddam AY, Moraveji SA, Ravandi BF. Prevalence of Oral Mucosal Lesions and Their Association with Severity of Psoriasis among Psoriatic Patients Referred To Dermatology Clinic: A Cross-Sectional Study in Kashan/Iran. Open Access Maced J Med Sci 2017;5(7):978-982. https://doi.org/10.3889/oamjms.2017.189.

Elman SA, Weinblatt M, Merola JF. Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg. 2018;37(3):173-181. https://doi.org/10.12788/j.sder.2018.045.

Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9-20. https://doi.org/10.1590/abd1806-4841.20153038.

Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343-350. https://doi.org/10.1016/j.clindermatol.2013.11.001.

Aurangabadkar SJ. Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol. 2013;79 Suppl 7:S10-S17. https://doi.org/10.4103/0378-6323.115506.

Chiu HY, Wang TS, Chen PH, Hsu SH, Tsai YC, Tsai TF. Psoriasis in Taiwan: From epidemiology to new treatments. Dermatologica Sinica. 2018;36(3):115-123. https://doi.org/10.1016/j.dsi.2018.06.001.

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590.

Malekzadeh MM, Vahedi H, Gohari K, Mehdipour P, Sepanlou SG, Ebrahimi Daryani N, Zali MR, Mansour Ghanaei F, Safaripour A, Aghazadeh R, Vossoughinia H, Fakheri H, Somi MH, Maleki I, Hoseini V, Ghadir MR, Daghaghzadeh H, Adibi P, Tavakoli H, Taghavi A, Zahedi MJ, Amiriani T, Tabib M, Alipour Z, Nobakht H, et al. Emerging Epidemic of Inflammatory Bowel Disease in a Middle Income Country: A Nation-wide Study from Iran. Arch Iran Med. 2016;19(1):2-15.

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1.

Alikhani M, Khalighinejad N, Ghalaiani P, Khaleghi MA, Askari E, Gorsky M. Immunologic and psychologic parameters associated with geographic tongue. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(1):68-71. https://doi.org/10.1016/j.oooo.2014.03.007.

Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin. 2004;22(4):349-vii. https://doi.org/10.1016/j.det.2004.03.010.

Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17 Suppl 2:1-5. https://doi.org/10.1046/j.1468-3083.17.s2.1.x.

Floreani A, Betterle C, Baragiotta A, Martini S, Venturi C, Basso D, Pittoni M, Chiarelli S, Sategna Guidetti C. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis. 2002;34(4):258-261. https://doi.org/10.1016/s1590-8658(02)80145-1.

Panetta F, Nobili V, Sartorelli MR, Papa RE, Ferretti F, Alterio A, Diamanti A. Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management. Paediatr Drugs. 2012;14(1):35-41. https://doi.org/10.2165/11593150-000000000-00000.

Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, Linares A, Veronesi L, Fuentes D, Zauli D, Bianchi FB. Celiac disease in autoimmune cholestatic liverliver disorders. Am J Gastroenterol. 2002;97(10):2609-2613. https://doi.org/10.1111/j.1572-0241.2002.06031.x

Brazier F, Delcenserie R, Sevestre H, Delamarre J, Capron J-P. Primary sclerosing cholangitis and coeliac disease: beneficial effect of gluten-free diet on the liver. European Journal of Gastroenterology & Hepatology. 1994;6(2):183-186.

Cadahía V, Rodrigo L, Fuentes D, Riestra S, de Francisco R, Fernández M. Celiac disease (CD), ulcerative colitis (UC), and primary sclerosing cholangitis (PSC) in one patient: a family study. Rev Esp Enferm Dig. 2005;97(12):907-913. https://doi.org/10.4321/s1130-01082005001200007. (English.Spanish).

Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525-540. https://doi.org/10.1111/j.13652036.2010.04556.x.

Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722- 727. https://doi.org/10.1111/ced.12672

Myśliwiec H, Baran A, Harasim-Symbor E, Myśliwiec P, Milewska AJ, Chabowski A, Flisiak I. Serum fatty acid profile in psoriasis and its comorbidity. Arch Dermatol Res. 2017;309(5):371-380. https://doi.org/10.1007/s00403-017-1748-x.

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322. https://doi.org/10.1161/CIR.0000000000000152.

Ma L, Li M, Wang H, Li Y, Bai B. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Arch Dermatol Res. 2014;306(3):247-251. https://doi.org/10.1007/s00403-013-1437-3.

Miller IM, Skaaby T, Ellervik C, Jemec GB. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol. 2013;169(6):1180- 1187. https://doi.org/10.1111/bjd.12490.

Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345-352. https://doi.org/10.1016/j.jaad.2018.02.040.

Khalid U, Ahlehoff O, Gislason GH, Kristensen SL, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743-748. https://doi.org/10.1002/ejhf.113.

Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010;24(12):1371-1377. https://doi.org/10.1111/j.14683083.2010.03656.x.

Jung KJ, Kim TG, Lee JW, Lee M, Oh J, Lee SE, Chang HJ, Jee SH, Lee MG. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15-year nationwide population-based cohort study. J Dermatol. 2019;46(10):859-866. https://doi.org/10.1111/1346-8138.15052.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reductionto cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. https://doi.org/10.1016/S0140-6736(17)32814-3.

Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD. Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. J Rheumatol. 2018;45(3):378-384. https://doi.org/10.3899/jrheum.170379.

Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):559- 568. https://doi.org/10.1586/14737167.2014.914437.

Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-930. https://doi.org/10.1016/j.jaad.2012.04.039.

McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019;50(4):892-906. https://doi.org/10.1016/j.immuni.2019.03.021.

Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, Fleming C, Hu X, Zhang HG, Weichselbaum R, Fu YX, Tieri D, Rouchka EC, Zheng J, Yan J. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. J Invest Dermatol. 2019;139(1):146-156. https://doi.org/10.1016/j.jid.2018.07.025.

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. https://doi.org/10.1016/S01406736(20)32549-6.

Griffiths CE, Barker JN. Pathogenesis and clinical featuresfeatures of psoriasis. Lancet. 2007;370(9583):263271. https://doi.org/10.1016/S0140-6736(07)61128-3.

Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol. 2019;5(3):141-150. https://doi.org/10.1016/j.ijwd.2019.04.021.

Bröms G, Haerskjold A, Granath F, Kieler H, Pedersen L, Berglind IA. Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes: A Population-based Cohort Study from Denmark and Sweden. Acta Derm Venereol. 2018;98(8):728-734. https://doi.org/10.2340/00015555-2923.

Johnson MA, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol. 2013;44(2):166-72. https://doi.org/10.1007/s12016-012-8305-3.

Batycka-Baran A, Maj J, Wolf R, Szepietowski JC. The new insight into the role of antimicrobial proteins alarmins in the immunopathogenesis of psoriasis. J Immunol Res. 2014;2014:628289. https://doi.org/10.1155/2014/628289.

Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218-224. https://doi.org/10.1016/j.jaad.2008.09.022.

Lønnberg AS, Skov L, Duffy DL, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Genetic Factors Explain Variation in the Age at Onset of Psoriasis: A Populationbased Twin Study. Acta Derm Venereol. 2016;96(1):35-38. https://doi.org/10.2340/00015555-2171.

Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8(1):1-12. https://doi.org/10.1038/sj.gene.6364351.




Загрузок PDF: 184
Опубликован
2023-03-02
Как цитировать
1.
Брынина АВ, Гимхан ДР, Викрамаге АИ. КОМОРБИДНЫЕ СОСТОЯНИЯ ПРИ ПСОРИАЗЕ. Журнал ГрГМУ (Journal GrSMU) [Интернет]. 2 март 2023 г. [цитируется по 29 март 2024 г.];21(1):12-8. доступно на: http://journal-grsmu.by/index.php/ojs/article/view/3004